Trials Show Operation Warp Speed Partner Moderna’s COVID Vaccine Is 94.5% Effective
Pharmaceutical company and Operation Warp Speed partner, Moderna, said Monday its COVID-19 vaccine was found over 94.5 percent effective in a major trial, giving another glimpse of hope a week after competitor Pfizer announced its own vaccine candidate had similar levels of efficacy.
The trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S, the company said in a statement.
The results are truly striking, said Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Disease.
More good news.